{
    "clinical_study": {
        "@rank": "111094", 
        "arm_group": [
            {
                "arm_group_label": "ALS-008176", 
                "arm_group_type": "Experimental", 
                "description": "ALS-008176 drug substance for oral suspension"
            }, 
            {
                "arm_group_label": "vehicle alone", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle alone"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo\n      control in the respiratory syncytial virus challenge model."
        }, 
        "brief_title": "A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model", 
        "condition": "Respiratory Syncytial Virus Infections", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Syncytial Virus Infections", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 45 years, inclusive.\n\n          -  In good health with no history of major medical conditions\n\n          -  A total body weight \u2265 50 kg and a body mass index (BMI) of > 18kg/m2.\n\n        Exclusion Criteria:\n\n          -  Acute or chronic medical illness\n\n          -  Positive for Human Immunodeficiency Virus, Hepatitis B or C\n\n          -  Nose or nasopharynx abnormalities\n\n          -  Abnormal lung function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094365", 
            "org_study_id": "ALS-8176-502"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALS-008176", 
                "intervention_name": "ALS-008176", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "vehicle alone", 
                "intervention_name": "vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "last_name": "Temi Giwa, MD, MSci", 
                "phone": "787 508 4287"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Retroscreen Virology Ltd"
            }, 
            "investigator": {
                "last_name": "Hosnieh Fathi, MD, MSc", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model", 
        "overall_official": {
            "affiliation": "Retroscreen Virology Ltd.", 
            "last_name": "Hosnieh Fathi, MD, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in viral load measurements.", 
            "safety_issue": "No", 
            "time_frame": "Baseline  to day 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094365"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alios Biopharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alios Biopharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}